NEK2 and glioblastoma: NEK2 was linked to inferior survival and poor prognoses in different cancers such as T-cell acute lymphoblastic leukemia, head and neck squamous cell carcinoma, bladder carcinoma, glioblastomas, hepatocellular carcinoma, and ovarian adenocarcinomas [45].